|
1
|
Gillam MP, Molitch ME, Lombardi G and
Colao A: Advances in the treatment of prolactinomas. Endocr Rev.
27:485–534. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Hu J, Zheng X, Zhang W and Yang H: Current
drug withdrawal strategy in prolactinoma patients treated with
cabergoline: A systematic review and meta-analysis. Pituitary.
18:745–751. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Colao A, Sarno AD, Cappabianca P, Briganti
F, Pivonello R, Somma CD, Faggiano A, Biondi B and Lombardi G:
Gender differences in the prevalence, clinical features and
response to cabergoline in hyperprolactinemia. Eur J Endocrinol.
148:325–331. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Beran RG: ‘Prolactinoma: Are dopamine
agonists still first choice?’. Intern Med J. 41:7572011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Casanueva FF, Molitch ME, Schlechte JA,
Abs R, Bonert V, Bronstein MD, Brue T, Cappabianca P, Colao A,
Fahlbusch R, et al: Guidelines of the pituitary society for the
diagnosis and management of prolactinomas. Clin Endocrinol (Oxf).
65:265–273. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Klibanski A: Clinical practice.
Prolactinomas. N Engl J Med. 362:1219–1226. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Jameera Begam A, Jubie S and Nanjan MJ:
Estrogen receptor agonists/antagonists in breast cancer therapy: A
critical review. Bioorg Chem. 71:257–274. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Gorski J, Wendell D, Gregg D and Chun TY:
Estrogens and the genetic control of tumor growth. Prog Clin Biol
Res. 396:233–243. 1997.PubMed/NCBI
|
|
9
|
Lv H, Li C, Gui S, Sun M, Li D and Zhang
Y: Effects of estrogen receptor antagonist on biological behavior
and expression of growth factors in the prolactinoma MMQ cell line.
J Neurooncol. 102:237–245. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kansra S, Yamagata S, Sneade L, Foster L
and Ben-Jonathan N: Differential effects of estrogen receptor
antagonists on pituitary lactotroph proliferation and prolactin
release. Mol Cell Endocrinol. 239:27–36. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lv H, Li C, Gui S and Zhang Y: Expression
of estrogen receptor α and growth factors in human prolactinoma and
its correlation with clinical features and gender. J Endocrinol
Invest. 35:174–180. 2012.PubMed/NCBI
|
|
12
|
Chaidarun SS, Swearingen B and Alexander
JM: Differential expression of estrogen receptor-beta (ER beta) in
human pituitary tumors: Functional interactions with ERα and a
tumor-specific splice variant. J Clin Endocrinol Metab.
83:3308–3315. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hay MP, Jiang D, Kozak M, Niwa M and Koong
AC: Inhibition of the IRE1α-XBP1 pathway: A new approach to
targeting the tumour microenvironment. Journal. 2015.
|
|
14
|
Chen Y and Brandizzi F: IRE1: ER stress
sensor and cell fate executor. Trends Cell Biol. 23:547–555. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Rigante M, Massimi L, Parrilla C, Galli J,
Caldarelli M, Di Rocco C and Paludetti G: Endoscopic
transsphenoidal approach versus microscopic approach in children.
Int J Pediatr Otorhinolaryngol. 75:1132–1136. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Nagykalnai T, Landherr L, Laczo I and Piko
B: Fulvestrant (Faslodex ®)for hormone sensitive breast
cancer. A review. Magy Onkol. 59:251–257. 2015.(In Hungarian).
|
|
17
|
Cao L, Gao H, Gui S, Bai G, Lu R, Wang F
and Zhang Y: Effects of the estrogen receptor antagonist
fulvestrant on F344 rat prolactinoma models. J Neurooncol.
116:523–531. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Leng L and Zhang Y: Effects of an estrogen
receptor antagonist on proliferation, prolactin secretion and
growth factor expression in the MMQ pituitary prolactinoma cell
line. J Clin Neurosci. 18:1694–1698. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Leng L and Zhang Y: Effects of an estrogen
receptor antagonist on proliferation, prolactin secretion and
growth factor expression in the MMQ pituitary prolactinoma cell
line. J Clin Neurosci. 18:1694–1698. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Koong AC, Chauhan V and Romero-Ramirez L:
Targeting XBP-1 as a novel anti-cancer strategy. Cancer Biol Ther.
5:756–759. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Henkel A and Green RM: The unfolded
protein response in fatty liver disease. Semin Liver Dis.
33:321–329. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Chen C and Zhang X: IRE1α-XBP1 pathway
promotes melanoma progression by regulating IL-6/STAT3 signaling. J
Transl Med. 15:422017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Chen L, Li Q, She T, Li H, Yue Y, Gao S,
Yan T, Liu S, Ma J and Wang Y: IRE1α-XBP1 signaling pathway, a
potential therapeutic target in multiple myeloma. Leuk Res.
49:7–12. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Rajapaksa G, Nikolos F, Bado I, Clarke R,
Gustafsson JA and Thomas C: ERβ decreases breast cancer cell
survival by regulating the IRE1/XBP-1 pathway. Oncogene.
34:4130–4141. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Jin C, Jin Z, Chen NZ, Lu M, Liu CB, Hu WL
and Zheng CG: Activation of IRE1α-XBP1 pathway induces cell
proliferation and invasion in colorectal carcinoma. Biochem Biophys
Res Commun. 470:75–81. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Liu R, Li X, Gao W, Zhou Y, Wey S, Mitra
SK, Krasnoperov V, Dong D, Liu S, Li D, et al: Monoclonal antibody
against cell surface GRP78 as a novel agent in suppressing PI3K/AKT
signaling, tumor growth, and metastasis. Clin Cancer Res.
19:6802–6811. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Rajapaksa G, Nikolos F, Bado I, Clarke R,
Gustafsson JÅ and Thomas C: ERβ decreases breast cancer cell
survival by regulating the IRE1/XBP-1 pathway. Oncogene.
34:4130–4141. 2015. View Article : Google Scholar : PubMed/NCBI
|
